FLT3 and leukemia: Due to this unresolved clinical issue, we tested navitoclax and hydroxyurea on Ba/F3 leukemia cells with FLT3-ITD (FLT3 with internal tandem duplication at 598) and therapy-associated FLT3-ITD/TKD mutants (FLT3-ITD+D835Y and FLT3-ITD+N676K).